RecruitingNot ApplicableNCT06208137

Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.

Using the Composite Immune Risk Score to Assess and Modulate the Patient's Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation, a Prospective, Multicenter, Randomized Controlled Study.

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Enrollment

456 participants

Start Date

Feb 29, 2024

Study Type

INTERVENTIONAL

Conditions

Transplant-Related Disorder

Summary

To assess the effectiveness of interventions including health monitoring and regular return follow-up reminders for patients with a high Composite Immune Risk Score.

Eligibility

Min Age: 16 Years

Inclusion Criteria3

\) Patients must be ≥ 16 years of age;
\) Patients receiving haploidentical allo-HSCT;
\) Patients have to sign an informed consent form before the start of the research procedure.

Exclusion Criteria3

\) Tandem transplantation or multiple transplantations;
\) Mental or other medical conditions that make the patients unable to comply with the research treatment and monitoring requirements;
\) Patients who are ineligible for the study due to other factors, or will bear great risk if participating in the study.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.